442 related articles for article (PubMed ID: 27515048)
21. Targeting the Toll-like receptor pathway as a therapeutic strategy for neonatal infection.
Dias ML; O'Connor KM; Dempsey EM; O'Halloran KD; McDonald FB
Am J Physiol Regul Integr Comp Physiol; 2021 Dec; 321(6):R879-R902. PubMed ID: 34612068
[TBL] [Abstract][Full Text] [Related]
22. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system.
Netea MG; van der Graaf C; Van der Meer JW; Kullberg BJ
J Leukoc Biol; 2004 May; 75(5):749-55. PubMed ID: 15075354
[TBL] [Abstract][Full Text] [Related]
23. Innate immunity and toll-like receptors: clinical implications of basic science research.
Abreu MT; Arditi M
J Pediatr; 2004 Apr; 144(4):421-9. PubMed ID: 15069387
[TBL] [Abstract][Full Text] [Related]
24. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
25. Toll-like receptors and their role in gastrointestinal disease.
Testro AG; Visvanathan K
J Gastroenterol Hepatol; 2009 Jun; 24(6):943-54. PubMed ID: 19638078
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia and hypoxia-inducible factor-1α provoke toll-like receptor signalling-induced inflammation in rheumatoid arthritis.
Hu F; Mu R; Zhu J; Shi L; Li Y; Liu X; Shao W; Li G; Li M; Su Y; Cohen PL; Qiu X; Li Z
Ann Rheum Dis; 2014 May; 73(5):928-36. PubMed ID: 23644550
[TBL] [Abstract][Full Text] [Related]
27. Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists.
Federico S; Pozzetti L; Papa A; Carullo G; Gemma S; Butini S; Campiani G; Relitti N
J Med Chem; 2020 Nov; 63(22):13466-13513. PubMed ID: 32845153
[TBL] [Abstract][Full Text] [Related]
28. Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis.
Goh FG; Midwood KS
Rheumatology (Oxford); 2012 Jan; 51(1):7-23. PubMed ID: 21984766
[TBL] [Abstract][Full Text] [Related]
29. Toll-Like Receptors as Drug Targets in the Intestinal Epithelium.
McKernan DP
Handb Exp Pharmacol; 2022; 276():291-314. PubMed ID: 34783909
[TBL] [Abstract][Full Text] [Related]
30. Toll-Like Receptor Pathways in Autoimmune Diseases.
Chen JQ; Szodoray P; Zeher M
Clin Rev Allergy Immunol; 2016 Feb; 50(1):1-17. PubMed ID: 25687121
[TBL] [Abstract][Full Text] [Related]
31. Development of TLR inhibitors for the treatment of autoimmune diseases.
Barrat FJ; Coffman RL
Immunol Rev; 2008 Jun; 223():271-83. PubMed ID: 18613842
[TBL] [Abstract][Full Text] [Related]
32. Innate immunity in systemic sclerosis pathogenesis.
O'Reilly S
Clin Sci (Lond); 2014 Mar; 126(5):329-37. PubMed ID: 24219159
[TBL] [Abstract][Full Text] [Related]
33. Toll-like receptors as sensors of pathogens.
Hallman M; Rämet M; Ezekowitz RA
Pediatr Res; 2001 Sep; 50(3):315-21. PubMed ID: 11518816
[TBL] [Abstract][Full Text] [Related]
34. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation?
Andreakos E; Foxwell B; Feldmann M
Immunol Rev; 2004 Dec; 202():250-65. PubMed ID: 15546398
[TBL] [Abstract][Full Text] [Related]
35. [Toll-like receptors and their role in regulation of the inflammatory response in sepsis].
Krawczyk-Michalak K; Glapiński A; Brzezińska-Błaszczyk E
Anestezjol Intens Ter; 2008; 40(4):253-59. PubMed ID: 19517667
[TBL] [Abstract][Full Text] [Related]
36. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy.
De Rycke L; Vandooren B; Kruithof E; De Keyser F; Veys EM; Baeten D
Arthritis Rheum; 2005 Jul; 52(7):2146-58. PubMed ID: 15986373
[TBL] [Abstract][Full Text] [Related]
37. [Antiinfective host defense mechanism: toll-like receptors and innate immunity].
Takesue Y; Ohge H; Kohyama M; Imamura Y; Murakami Y; Sueda T
Nihon Geka Gakkai Zasshi; 2003 Jul; 104(7):494-8. PubMed ID: 12884772
[TBL] [Abstract][Full Text] [Related]
38. Basic understanding and therapeutic approaches to target toll-like receptors in cancerous microenvironment and metastasis.
Khajeh Alizadeh Attar M; Anwar MA; Eskian M; Keshavarz-Fathi M; Choi S; Rezaei N
Med Res Rev; 2018 Sep; 38(5):1469-1484. PubMed ID: 29283184
[TBL] [Abstract][Full Text] [Related]
39. Innate immunity and toll-like receptor antagonists: a potential role in the treatment of cardiovascular diseases.
Lin E; Freedman JE; Beaulieu LM
Cardiovasc Ther; 2009; 27(2):117-23. PubMed ID: 19426249
[TBL] [Abstract][Full Text] [Related]
40. Toll-like receptors as interferon-regulated genes and their role in disease.
Khoo JJ; Forster S; Mansell A
J Interferon Cytokine Res; 2011 Jan; 31(1):13-25. PubMed ID: 21198355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
